Developer docs
API playgroundTry for free, no card

Search company profiles

Panome Bio

Full company profile

uuid0000duu

Namestring
Panome Bio
Legal namestring
Panome Bio
Websiteurl
panomebio.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Panome Bio is a CLIA-certified multi-omics contract research organization (CRO) headquartered in the Cortex Innovation Community in St. Louis, Missouri. Founded in 2022, the company provides liquid chromatography–mass spectrometry (LC/MS)-based services spanning metabolomics, proteomics, transcriptomics, and exposomics to biopharmaceutical companies, biotechnology firms, and academic research institutions engaged in biomarker discovery, mechanism-of-action studies, patient stratification, and clinical-trial support. The portfolio is anchored by Next-Generation Metabolomics® (four complementary LC-MS assays covering polar and lipid metabolites) and Discovery Proteomics (Seer Proteograph XT coupled with a Thermo Fisher Orbitrap Astral mass spectrometer), augmented by specialized offerings such as TissueBridge™ FFPE metabolomics, Global Phosphoproteomics, Targeted Proteomics, PRMT5 Metabolomics Panel, and Discovery and Targeted Exposomics™.

The company's core proprietary technology is MassID™, a cloud-based computational platform that integrates deep learning for peak detection and noise filtering with a 280,000-compound reference database and probability-based FDR-controlled metabolite identification. MassID underpins the Next-Generation Metabolomics® service and feeds an integrated multi-omics analysis platform that interweaves metabolomics, proteomics, and transcriptomics datasets onto shared biochemical networks for pathway-level interpretation. Panome Bio monetizes through project-based, quote-priced CRO engagements with biopharma, biotech, and academic customers, acquired via scientific conference participation (AACR, ASMS, US HUPO, ASCO, Society of Toxicology, EACR, Festival of Biologics), webinars, content marketing, and strategic channel partnerships such as TD2 Oncology. As of early 2026 the company had raised approximately $6M in growth financing (Telegraph Hill Partners, BioGenerator Ventures), obtained CLIA certification, and scaled its multi-omics service menu beyond metabolomics into clinical-grade biomarker workflows.

Short descriptiontext

Panome Bio is a CLIA-certified multi-omics CRO offering metabolomics, proteomics, transcriptomics, and exposomics services to biopharma, biotech, and academic clients, anchored by its MassID™ deep-learning computational platform and proprietary LC-MS workflows.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSaint Louis, United States
HQ citystring
Saint Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
multi-omics services, metabolomics profiling, proteomics analysis, contract research organization, biomarker discovery
Industry3 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
NAICS code3 codes
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Multi-omics Contract Research Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services (CRO)
TypeProfessional Services
Description

Panome Bio operates as a CLIA-certified multi-omics contract research organization providing laboratory services to biopharma, biotech, and academic researchers. Services are project-based, with customers submitting samples for analysis. Services are available to biopharma, biotech, and academic partners. Pricing is quote-based.

panomebio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing for CRO services
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is quote-based / not publicly disclosed. Services are project-specific based on sample types, number of samples, and analytical services requested.

panomebio.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Panome Bio is a CLIA-certified multi-omics contract research organization (CRO) providing metabolomics, proteomics, transcriptomics, and exposomics services to biopharma, biotech, and academic research clients. The company leverages liquid chromatography-mass spectrometry (LC-MS) technology combined with proprietary computational pipelines (MassID™) to deliver untargeted profiling across biofluids, tissues, FFPE samples, and cell cultures, with data turnaround in 4-6 weeks. Services are project-based and quote-priced, supporting biomarker discovery, mechanism of action studies, patient stratification, and clinical trial biomarker analysis.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Panome Bio is a multi-omics contract research organization offering a comprehensive portfolio of services built around Next-Generation Metabolomics® and Discovery Proteomics as core platforms. The service portfolio includes specialized metabolomics offerings (Next-Generation Lipidomics®, Metabolic Flux Analysis, PRMT5 Metabolomics Panel, TissueBridge™ FFPE Metabolomics, Microbiome Function Analysis, Cell Surface Membrane Lipidomics) and proteomics services (Discovery Proteomics for Biofluids and Tissues, Targeted Proteomics, Global Phosphoproteomics, Cell Surface Proteomics). Additional offerings include Transcriptomics, Integrated Multi-omics, Cell Surface Multi-omics, and Exposomics (Discovery Exposomics™ and Targeted Exposomics™). MassID™ serves as the proprietary computational identification engine powering Next-Generation Metabolomics®, providing AI-driven metabolite identification with confidence scoring. All services are delivered through a unified workflow with data turnaround in 4-6 weeks.

Product and service1 record
1Next-Generation Metabolomics®
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1TD2 Oncology
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-27
Description

Panome Bio and TD2 Oncology expanded their strategic partnership to provide integrated multi-omics profiling combined with translational and clinical oncology expertise. The collaboration enables researchers to access Panome Bio's capabilities in metabolomics, proteomics, transcriptomics, and exposomics alongside TD2's expertise in evaluating therapeutic candidates in clinically relevant settings. Designed to support biomarker discovery, mechanism-of-action studies, and clinical development including patient selection strategies and biomarker-driven trial design.

prnewswire.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-16
Description

Panome Bio and Audubon Bioscience partnered on end-to-end FFPE solutions, combining Panome Bio's TissueBridge FFPE metabolomics service with Audubon Bioscience's sample supply capabilities for comprehensive archived tissue analysis.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-11-01
Description

Panome Bio was added to Seer's Centers of Excellence (COE) Program, recognizing the company's excellence in proteomics analysis using Seer's Proteograph XT platform coupled with the Thermo Fisher Orbitrap Astral mass spectrometer. The COE designation reflects Panome Bio's advanced capabilities in biofluid proteomics.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Emerging separation-science company enabling high-throughput, high-resolution omics measurements. Represents a future technology-input alternative to current LC-MS pipelines Panome Bio depends on.

TypeDirect peer
Description

Largest dedicated metabolomics CRO, offering untargeted metabolomics and lipidomics services to biopharma and academic clients. Panome Bio directly competes on the same Next-Generation Metabolomics value proposition with its own MassID pipeline.

TypeBroad incumbent
Description

Global mega-CRO with significant metabolomics, proteomics, and exposomics service offerings across pharma, food, and environmental end markets. Competes broadly with Panome Bio from a scale and breadth advantage rather than specialization.

TypeDirect peer
Description

Proteomics platform offering high-plex protein biomarker measurement (SomaScan) to biopharma and academic clients. Overlaps with Panome Bio's biofluid proteomics and biomarker discovery offerings.

TypeRegional player
Description

Asia-headquartered multi-omics service provider with metabolomics, proteomics, and transcriptomics offerings. Overlapping capability but primarily serving Asia-Pacific customers; competes in cross-border biopharma accounts.

TypeDirect peer
Description

Specialist metabolomics CRO offering targeted and quantitative metabolomics panels (similar to Panome Bio's Targeted Metabolomics) for pharma, clinical research, and academic customers across the same buyer base.

TypeDirect peer
Description

Proteomics company providing high-multiplex biomarker discovery and targeted protein panels for translational and clinical research. Competes directly with Panome Bio's discovery and targeted proteomics services.

TypeDirect peer
Description

Contract proteomics services firm specializing in mass spectrometry-based protein profiling and biomarker discovery for pharma and academic clients — directly comparable CRO model to Panome Bio's proteomics arm.

TypeBroad incumbent
Description

Large CRO with established discovery, biomarker, and multi-omics service lines serving biopharma. Comparable as a broader-services competitor that can bundle omics into enterprise contracts.

TypeBroad incumbent
Description

Mass spectrometry and proteomics instrumentation vendor that also offers applications/services in metabolomics and proteomics. Adjacent competitor with overlapping analytical capability but a fundamentally different business model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Panome Bio

Multi-omics Contract Research Servicespanomebio.com

Panome Bio is a CLIA-certified multi-omics CRO offering metabolomics, proteomics, transcriptomics, and exposomics services to biopharma, biotech, and academic clients, anchored by its MassID™ deep-learning computational platform and proprietary LC-MS workflows.

What Panome Bio does

Panome Bio is a CLIA-certified multi-omics contract research organization (CRO) headquartered in the Cortex Innovation Community in St. Louis, Missouri. Founded in 2022, the company provides liquid chromatography–mass spectrometry (LC/MS)-based services spanning metabolomics, proteomics, transcriptomics, and exposomics to biopharmaceutical companies, biotechnology firms, and academic research institutions engaged in biomarker discovery, mechanism-of-action studies, patient stratification, and clinical-trial support. The portfolio is anchored by Next-Generation Metabolomics® (four complementary LC-MS assays covering polar and lipid metabolites) and Discovery Proteomics (Seer Proteograph XT coupled with a Thermo Fisher Orbitrap Astral mass spectrometer), augmented by specialized offerings such as TissueBridge™ FFPE metabolomics, Global Phosphoproteomics, Targeted Proteomics, PRMT5 Metabolomics Panel, and Discovery and Targeted Exposomics™.

The company's core proprietary technology is MassID™, a cloud-based computational platform that integrates deep learning for peak detection and noise filtering with a 280,000-compound reference database and probability-based FDR-controlled metabolite identification. MassID underpins the Next-Generation Metabolomics® service and feeds an integrated multi-omics analysis platform that interweaves metabolomics, proteomics, and transcriptomics datasets onto shared biochemical networks for pathway-level interpretation. Panome Bio monetizes through project-based, quote-priced CRO engagements with biopharma, biotech, and academic customers, acquired via scientific conference participation (AACR, ASMS, US HUPO, ASCO, Society of Toxicology, EACR, Festival of Biologics), webinars, content marketing, and strategic channel partnerships such as TD2 Oncology. As of early 2026 the company had raised approximately $6M in growth financing (Telegraph Hill Partners, BioGenerator Ventures), obtained CLIA certification, and scaled its multi-omics service menu beyond metabolomics into clinical-grade biomarker workflows.

Panome Bio firmographics

Firmographics
Name
Panome Bio
Legal name
Panome Bio
Website
https://panomebio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Panome Bio is a CLIA-certified multi-omics CRO offering metabolomics, proteomics, transcriptomics, and exposomics services to biopharma, biotech, and academic clients, anchored by its MassID™ deep-learning computational platform and proprietary LC-MS workflows.
Ownership category
akta.pro rank

Panome Bio industry classification

Industry
Product category
Multi-omics Contract Research Services
NAICS
Medical Laboratories (621511), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Keywords

  • Multi-omics services
  • Metabolomics profiling
  • Proteomics analysis
  • Contract research organization
  • Biomarker discovery

Where Panome Bio is headquartered

Location

Headquarters

HQ city
Saint Louis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Panome Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services (CRO): Panome Bio operates as a CLIA-certified multi-omics contract research organization providing laboratory services to biopharma, biotech, and academic researchers. Services are project-based, with customers submitting samples for analysis. Services are available to biopharma, biotech, and academic partners. Pricing is quote-based.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing for CRO services

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Panome Bio product offering

Product offering

Core offering

Panome Bio is a CLIA-certified multi-omics contract research organization (CRO) providing metabolomics, proteomics, transcriptomics, and exposomics services to biopharma, biotech, and academic research clients. The company leverages liquid chromatography-mass spectrometry (LC-MS) technology combined with proprietary computational pipelines (MassID™) to deliver untargeted profiling across biofluids, tissues, FFPE samples, and cell cultures, with data turnaround in 4-6 weeks. Services are project-based and quote-priced, supporting biomarker discovery, mechanism of action studies, patient stratification, and clinical trial biomarker analysis.

Product overview

Panome Bio is a multi-omics contract research organization offering a comprehensive portfolio of services built around Next-Generation Metabolomics® and Discovery Proteomics as core platforms. The service portfolio includes specialized metabolomics offerings (Next-Generation Lipidomics®, Metabolic Flux Analysis, PRMT5 Metabolomics Panel, TissueBridge™ FFPE Metabolomics, Microbiome Function Analysis, Cell Surface Membrane Lipidomics) and proteomics services (Discovery Proteomics for Biofluids and Tissues, Targeted Proteomics, Global Phosphoproteomics, Cell Surface Proteomics). Additional offerings include Transcriptomics, Integrated Multi-omics, Cell Surface Multi-omics, and Exposomics (Discovery Exposomics™ and Targeted Exposomics™). MassID™ serves as the proprietary computational identification engine powering Next-Generation Metabolomics®, providing AI-driven metabolite identification with confidence scoring. All services are delivered through a unified workflow with data turnaround in 4-6 weeks.

Differentiator

Problem solved

Functional benefit

Products and services

  • Next-Generation Metabolomics®

Companies that use Panome Bio

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Panome Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Panome Bio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • TD2 OncologycoreStrategic or Co-development Partner · 27 May 2026Panome Bio and TD2 Oncology expanded their strategic partnership to provide integrated multi-omics profiling combined with translational and clinical oncology expertise. The collaboration enables researchers to access Panome Bio's capabilities in metabolomics, proteomics, transcriptomics, and exposomics alongside TD2's expertise in evaluating therapeutic candidates in clinically relevant settings. Designed to support biomarker discovery, mechanism-of-action studies, and clinical development including patient selection strategies and biomarker-driven trial design.
  • Audubon BioscienceminorStrategic or Co-development Partner · 16 April 2026Panome Bio and Audubon Bioscience partnered on end-to-end FFPE solutions, combining Panome Bio's TissueBridge FFPE metabolomics service with Audubon Bioscience's sample supply capabilities for comprehensive archived tissue analysis.
  • Seer Bio (Centers of Excellence Program)coreTechnology or Integration · 1 November 2023Panome Bio was added to Seer's Centers of Excellence (COE) Program, recognizing the company's excellence in proteomics analysis using Seer's Proteograph XT platform coupled with the Thermo Fisher Orbitrap Astral mass spectrometer. The COE designation reflects Panome Bio's advanced capabilities in biofluid proteomics.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Panome Bio competitors and assessment

Company assessment

Emerging players

  • MOBILion Systems: Emerging separation-science company enabling high-throughput, high-resolution omics measurements. Represents a future technology-input alternative to current LC-MS pipelines Panome Bio depends on.

Direct peers

  • Metabolon: Largest dedicated metabolomics CRO, offering untargeted metabolomics and lipidomics services to biopharma and academic clients. Panome Bio directly competes on the same Next-Generation Metabolomics value proposition with its own MassID pipeline.
  • SomaLogic: Proteomics platform offering high-plex protein biomarker measurement (SomaScan) to biopharma and academic clients. Overlaps with Panome Bio's biofluid proteomics and biomarker discovery offerings.
  • Biocrates Life Sciences: Specialist metabolomics CRO offering targeted and quantitative metabolomics panels (similar to Panome Bio's Targeted Metabolomics) for pharma, clinical research, and academic customers across the same buyer base.
  • Olink: Proteomics company providing high-multiplex biomarker discovery and targeted protein panels for translational and clinical research. Competes directly with Panome Bio's discovery and targeted proteomics services.
  • Proteome Sciences: Contract proteomics services firm specializing in mass spectrometry-based protein profiling and biomarker discovery for pharma and academic clients — directly comparable CRO model to Panome Bio's proteomics arm.

Broad incumbents

  • Eurofins Scientific: Global mega-CRO with significant metabolomics, proteomics, and exposomics service offerings across pharma, food, and environmental end markets. Competes broadly with Panome Bio from a scale and breadth advantage rather than specialization.
  • Charles River Laboratories: Large CRO with established discovery, biomarker, and multi-omics service lines serving biopharma. Comparable as a broader-services competitor that can bundle omics into enterprise contracts.
  • Bruker: Mass spectrometry and proteomics instrumentation vendor that also offers applications/services in metabolomics and proteomics. Adjacent competitor with overlapping analytical capability but a fundamentally different business model.

Regional players

  • BGI Genomics: Asia-headquartered multi-omics service provider with metabolomics, proteomics, and transcriptomics offerings. Overlapping capability but primarily serving Asia-Pacific customers; competes in cross-border biopharma accounts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Panome Bio social profiles

Digital presence

Panome Bio compliance and trust

Trust signal

Compliance1 record

Panome Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Panome Bio leadership team

Management profile

Number of profiles

Profiles8 records

Panome Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Panome Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Panome Bio

What does Panome Bio do?

Panome Bio is a CLIA-certified multi-omics contract research organization (CRO) providing metabolomics, proteomics, transcriptomics, and exposomics services to biopharma, biotech, and academic research clients. The company leverages liquid chromatography-mass spectrometry (LC-MS) technology combined with proprietary computational pipelines (MassID™) to deliver untargeted profiling across biofluids, tissues, FFPE samples, and cell cultures, with data turnaround in 4-6 weeks. Services are project-based and quote-priced, supporting biomarker discovery, mechanism of action studies, patient stratification, and clinical trial biomarker analysis.

Is Panome Bio a public or private company?

Panome Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Panome Bio founded?

Panome Bio was founded in 2022. It employs 11 to 50 people.

Where is Panome Bio based?

Panome Bio is headquartered in Saint Louis, United States, in the North America region.

How does Panome Bio make money?

One revenue line is on record: contract Research Services (CRO).

Who are Panome Bio's main competitors?

MOBILion Systems is listed as an emerging player. Direct peers are Metabolon, SomaLogic, Biocrates Life Sciences, Olink and Proteome Sciences. Broad incumbents are Eurofins Scientific, Charles River Laboratories and Bruker. BGI Genomics is listed as a regional player.

Does Panome Bio have an API?

No public API is recorded for Panome Bio.

What industry is Panome Bio in?

Panome Bio's product category is Multi-omics Contract Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGANAB, Proteomics & Mass Spectrometry Services. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireTD2 Oncology and Panome Bio Partner to Advance Translational Oncology Through Integrated Multi-Omics CapabilitiesPanome Bio, a CLIA-certified multi-omics contract research organization, and TD2 Oncology, an oncology-focused CRO, announced an expansion of their strategic partnership to provide integrated multi-omics profiling combined with translational and clinical oncology expertise. The collaboration enables researchers to access Panome Bio's capabilities in metabolomics, proteomics, transcriptomics, and exposomics alongside TD2's expertise in evaluating therapeutic candidates in clinically relevant settings. The partnership is designed to support biomarker discovery, mechanism-of-action studies, and clinical development efforts including patient selection strategies and biomarker-driven trial design.NewswiseTD2 Oncology and Panome Bio Partner to Advance Translational Oncology Through Integrated Multi-Omics CapabilitiesPanome Bio and TD2 Oncology announced an expansion of their strategic partnership to provide researchers with integrated access to translational oncology expertise, clinical development, and comprehensive multi-omics analysis under a coordinated framework. The collaboration pairs TD2's clinical oncology expertise with Panome Bio's multi-omics capabilities in metabolomics, proteomics, transcriptomics, and exposomics, enabling biomarker discovery and a more connected approach to studying cancer biology from research models through clinical trials. The partnership is designed to help drug developers better characterize therapeutic response and connect molecular data across all stages of drug development.PR NewswirePanome Bio and Audubon Bioscience Partner to Deliver End-to-End FFPE Biospecimen and Metabolomics Solutions for Cancer ResearchersPanome Bio and Audubon Bioscience announced a strategic partnership at the AACR Annual Meeting 2026 in San Diego to provide end-to-end solutions for cancer researchers, combining ethically sourced FFPE biospecimen procurement with discovery metabolomics analysis. The collaboration integrates Audubon Bioscience's global biobanking network spanning 120+ clinical sites across 10 countries with Panome Bio's TissueBridge FFPE Metabolomics platform, enabling researchers to access previously untapped clinical archives for metabolic profiling. The partnership addresses a longstanding bottleneck in cancer research by offering a coordinated pathway from tissue acquisition through comprehensive metabolic analysis.GenengnewsUpping the Profiling of Chemical Exposures in the Omics SciencesPanome Bio, a multi-omics contract research organization, launched its exposomics service platform that provides chemical exposure profiling in biological samples, combining untargeted discovery capabilities with targeted quantification of 235 priority chemicals. The service addresses a significant gap in omics sciences, as environmental exposures from PFAS, pesticides, and other sources are estimated to drive 70–90% of chronic disease risk yet remain the least measured health determinants. The company positions exposomics as a tool to help explain drug response variability in clinical trials and patient stratification, connecting chemical exposures to molecular outcomes alongside its existing metabolomics, proteomics, and transcriptomics capabilities.PR NewswirePanome Bio Launches Exposomics Services to Measure the Chemical Drivers of Human DiseasePanome Bio, a multi-omics contract research organization headquartered in St. Louis, announced the launch of its exposomics platform, the first commercially available service providing comprehensive, unbiased chemical exposure profiling in biological samples, combining Discovery Exposomics screening over 32,000 compounds with Targeted Exposomics quantifying 235 priority chemicals. The platform addresses the estimated 70-90% of chronic disease risk driven by environmental exposures such as PFAS, pesticides, and industrial solvents, which remain among the least measured determinants of health outcomes. The service also offers significant applications for pharmaceutical development, enabling researchers to better understand inter-patient variability in drug response and trial outcomes.GenengnewsProcessing and Interpreting Untargeted Metabolomics Data for Biomarker Discovery and Drug DevelopmentPanome Bio, a contract research organization (CRO), launched MassID, a cloud-based computational platform designed to improve the processing and interpretation of untargeted LC/MS metabolomics data for biomarker discovery and drug development. The platform addresses a key challenge in metabolomics by providing an end-to-end pipeline with probability-based confidence scoring and a 280,000-metabolite database, enabling researchers to distinguish true metabolite signals from chemical noise. In validation testing on human plasma samples, MassID structurally identified more than 4,500 metabolites, including over 1,200 compounds with greater than 95% confidence.PR NewswirePanome Bio Introduces MassID™, a Major Advance in Untargeted Metabolomics Data Analysis for Biomarker Discovery and Drug DevelopmentPanome Bio announced the launch of MassID™, a cloud-based computational platform for untargeted LC/MS metabolomics data analysis that integrates deep learning and probabilistic confidence scoring to improve metabolite identification accuracy and coverage. The platform features a 280,000 metabolite database and demonstrated the ability to structurally identify over 4,500 metabolites in human plasma testing, including over 1,200 at a false discovery rate below 5%. MassID is now integrated into Panome Bio's metabolomics service offerings and is available immediately to biopharma, biotech, and academic partners.American City Business JournalsPanome Bio expands beyond metabolomics with new exposomics offeringPanome Bio, a St. Louis contract research organization, is launching a new exposomics capability to measure environmental chemicals such as herbicides and carcinogens in human samples. The company already works with six of the top 10 pharmaceutical companies.PanomebioIntegrated Multi-Omics ServicesPanome Bio is promoting its integrated multi-omic analysis services, which combine metabolomics, proteomics, and transcriptomics data to provide deeper insights into biochemical pathways. The company highlights the use of proprietary bioinformatics pipelines and databases to enhance biomarker discovery and identify actionable targets for cancer therapy.